Antibiotics

First Opinion By Jowa (Zhuo) Shi and Ateev Mehrotra

Inappropriately prescribed antibiotics will likely accompany the winter surge of Covid-19

Pharma By Ed Silverman

New bill would create a subscription payment model to jumpstart antibiotic development

Pharmalot By Ed Silverman

Doctors say antibiotic resistance is an issue — but most say they’re not part of the problem

First Opinion By Kevin Outterson and John Rex

We need new antimicrobials to prevent the next infectious disease crisis

Special Report By Gardiner Harris and Alex W. Palmer — The Wire

China has near-total control of the world’s antibiotic supply. Is America at risk as a result?

First Opinion By Isaac Stoner

Saving lives should be good business. Why doesn’t that apply to finding new antibiotics?

Pharmalot By Ed Silverman

WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’

Pharmalot By Ed Silverman

Pharmalittle: France indicts Sanofi over epilepsy drug risks; Trump talk of drug pricing in SOTU speech may backfire

First Opinion By Alba Tiley and Steve Brooks

Companies must responsibly manufacture the antimicrobials society needs

First Opinion By Allan Coukell

Antibiotics need a special place in the drug pricing debate

Pharmalot By Ed Silverman

Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year

First Opinion By Alex M. Azar II and Robert R. Redfield

U.S. continues to lead the fight against antibiotic resistance

Health By Helen Branswell

CDC report: 35,000 Americans die of antibiotic-resistant infections each year

First Opinion By Seema Verma

Seema Verma: CMS’s ‘expanded pathway’ for new antibiotics can help fight antimicrobial resistance

Pharmalot By Ed Silverman

Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial

Pharmalot By Ed Silverman

The use of antibiotics in food-producing livestock continues to drop in most of Europe

First Opinion By Manos Perros

Wanted: better policies and incentives to revitalize R&D for new antimicrobial drugs

Pharmalot By Ed Silverman

Pharmalittle: Opioid judge refuses to disqualify himself; Biocon to lower insulin price in some countries

Pharmalot By Ed Silverman

Pharmalittle: Pelosi plan rests with Dems who get big pharma bucks; Novartis recalls heartburn meds from U.S.

Pharmalot By Ed Silverman

Antibiotic resistance in food-producing animals surges in low- and middle-income countries

Biotech By Kate Sheridan

The next frontier for the microbiome: vaginal fluid transplants that take aim at a common condition

Pharmalot By Ed Silverman

Pharmalittle: Two drug makers may settle opioid case; FDA hands Sarepta a surprising setback

In the Lab By Helen Branswell

Everyone agrees this superbug is a threat. Few are willing to fund research to stop it

Health By Meghana Keshavan

Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge

First Opinion By Kevin Outterson and Helen W. Boucher

Most Read

Antibiotic resistance: the hidden threat lurking behind Covid-19

Antibiotics could dramatically reduce STIs, study says, raising tough new questions

Why your doctor’s advice to take all your antibiotics may be wrong

The superbug Candida auris is giving rise to warnings — and big questions

Flesh-eating bacteria: 5 things to know after a hiker’s almost-fatal infection

Scarlet fever, a disease of yore, is making a comeback in parts of the world

Pills for appendicitis? Surgery often not needed, study says

Patients with feared superbug shed large amounts of it from their skin, study says

All Coverage

Inappropriately prescribed antibiotics will likely accompany the winter surge of Covid-19

New bill would create a subscription payment model to jumpstart antibiotic development

Doctors say antibiotic resistance is an issue — but most say they’re not part of the problem

We need new antimicrobials to prevent the next infectious disease crisis

China has near-total control of the world’s antibiotic supply. Is America at risk as a result?

Saving lives should be good business. Why doesn’t that apply to finding new antibiotics?

WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’

Pharmalittle: France indicts Sanofi over epilepsy drug risks; Trump talk of drug pricing in SOTU speech may backfire

Companies must responsibly manufacture the antimicrobials society needs

Antibiotics need a special place in the drug pricing debate

Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year

U.S. continues to lead the fight against antibiotic resistance

CDC report: 35,000 Americans die of antibiotic-resistant infections each year

Seema Verma: CMS’s ‘expanded pathway’ for new antibiotics can help fight antimicrobial resistance

Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial

The use of antibiotics in food-producing livestock continues to drop in most of Europe

Wanted: better policies and incentives to revitalize R&D for new antimicrobial drugs

Pharmalittle: Opioid judge refuses to disqualify himself; Biocon to lower insulin price in some countries

Pharmalittle: Pelosi plan rests with Dems who get big pharma bucks; Novartis recalls heartburn meds from U.S.

Antibiotic resistance in food-producing animals surges in low- and middle-income countries

The next frontier for the microbiome: vaginal fluid transplants that take aim at a common condition

Pharmalittle: Two drug makers may settle opioid case; FDA hands Sarepta a surprising setback

Everyone agrees this superbug is a threat. Few are willing to fund research to stop it

Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge

Medicare payment rules hinder the fight against superbugs